Day One Biopharmaceuticals, Inc.
NASDAQ•DAWN
CEO: Dr. Jeremy Bender M.B.A., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-05-27
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
Contact Information
Market Cap
$1.03B
P/E (TTM)
-9.7
19.9
Dividend Yield
--
52W High
$13.20
52W Low
$5.64
52W Range
Rank53Top 76.1%
2.8
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Financial Dashboard
Q4 2025 Data
Revenue
$53.72M+0.00%
4-Quarter Trend
EPS
-$0.21+0.00%
4-Quarter Trend
FCF
-$17.65M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Product Revenue Surges Product revenue reached $155.4M, up 171.6% in 2025, driven by successful US commercial launch of OJEMDA.
Operating Loss Significantly Narrows Loss from operations improved $89.5M to $127.8M, primarily due to lower R&D expenses in 2025.
R&D Spend Decreases Research and development expenses decreased $79.6M to $148.1M, reflecting reduced upfront license milestone payments.
Pipeline Expansion Completed Acquisition of Mersana closed January 2026, adding Emi-Le, positioning company for oncology portfolio expansion.
Risk Factors
Continued Net Losses Expected Incurred $107.3M net loss in 2025; expects continued losses indefinitely, making profitability uncertain for foreseeable future.
OJEMDA Commercialization Dependency Near-term revenue highly dependent on successful OJEMDA commercialization; failure materially affects financial condition and stock price.
Clinical Trial Uncertainty Remains Clinical trials are expensive and time-consuming; earlier positive results may not predict later-stage success or regulatory approval.
Reliance on Third-Party Manufacturers Reliance on limited third parties for manufacturing and clinical trials introduces supply chain, quality, and operational risks.
Outlook
Tovorafenib Phase 3 Completion Expect FIREFLY-2 Phase 3 trial enrollment completion in H1 2026 to support full OJEMDA regulatory approval.
Emi-Le Clinical Data Update Plan to present clinical data for Emi-Le (ACC ADC) mid-2026 to support potential rapid development pathway.
DAY301 Program Update Plan to present initial clinical data for DAY301 (PTK7 ADC) in the second half of 2026.
Expand Targeted Oncology Pipeline Continue leveraging BD expertise to identify, acquire, and develop additional high-impact targeted oncology assets.
Peer Comparison
Revenue (TTM)
$262.60M
$236.19M
$198.55M
Gross Margin (Latest Quarter)
672.1%
100.0%
97.3%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ERAS | $4.37B | -31.3 | -33.1% | 11.5% |
| TERN | $3.74B | -40.3 | -30.0% | 0.3% |
| OLMA | $1.84B | -13.4 | -41.5% | 1.3% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
20.4%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:May 13, 2026
EPS:-$0.25
|Revenue:$54.60M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data